

Speaker Lecture Titles

Partial list of confirmed speakers.

Name	Country	Lecture Title
Claudio A. Cuello	Canada	NEW PERSPECTIVES OF NGF METABOLISM AND THE CHOLINERGIC SYSTEM IN PRECLINICAL ALZHEIMER'S
Liana Apostolova	USA	SPORADIC EARLY-ONSET ALZHEIMER'S DISEASE: PRELIMINARY LONGITUDINAL RESULTS FROM LEADS
Johannes Attems	UK	AGE ASSOCIATED TDP-43 PATHOLOGY
Tom Beach	USA	BIOPSIES FOR DIAGNOSTIC AND PROGRESSION BIOMARKERS IN NEURODEGENERATIVE DISEASE
Mathew Blurton Jones	USA	EXAMINING THE THERAPEUTIC POTENTIAL OF CRISPR-MODIFIED IPS-MICROGLIA
Mercè Boada	Spain	TBA
Guojun Bu	USA	CENTRAL AND PERIPHERAL APOE IN ALZHEIMER'S DISEASE
Samantha Budd-Haeberlein	USA	DEVELOPMENT OF THERAPEUTICS IN ALZHEIMER'S DISEASE
Luc Buee	France	TAU IMMUNOTHERAPY: INTRACELLULAR OU EXTRACELLULAR TARGET?
Frédéric Checler	France	BETA-SECRETASE-DERIVED C-TERMINAL FRAGMENTS OF BETA-APP AS EARLY TRIGGERS OF CELLULAR DYSFUNCTIONS AND ANATOMICAL STIGMATA IN ALZHEIMER'S DISEASE
Gaël Chételat	France	IMPACT OF PSYCHOAFFECTIVE FACTORS ON ALZHEIMER'S DISEASE RISK AND MEDITATION AS AN PROMISING PREVENTIVE APPROACH
Ornit Chiba-Falek	USA	MULTI-OMICS NAVIGATION OF ALZHEIMER'S AND PARKINSON'S GENETIC LANDSCAPES FROM SINGLE-CELL LENSES
Don Cleveland	USA	TRACING GLIA-INTO-NEURON CONVERSION IN THE AGED MOUSE BRAIN USING SINGLE CELL SPATIAL TRANSCRIPTOMICS
Jeffrey Cummings	USA	THE ALZHEIMER'S DISEASE DRUG DEVELOPMENT PIPELINE: THE CHANGING THERAPEUTIC LANDSCAPE
Bart De Strooper	Belgium	THE EARLY CELLULAR RESPONSES IN THE ALZHEIMER DISEASE BRAIN.
Marc Diamond	USA	DETERMINATION OF AMINO ACIDS CRITICAL TO TAU ASSEMBLY IN TAUOPATHIES
Karen Duff	UK	PATHOGENIC MECHANISMS IN THE TAUOPATHIES
Adam Fleisher	USA	EVOLUTION TOWARDS PRACTICAL BIOMARKERS FOR RESEARCH AND DIAGNOSIS IN ALZHEIMER'S DISEASE
Nick Fox	United Kingdom	ULTRAFAST MRI AND BIOMARKERS TO IMPROVE DIAGNOSIS RATES IN DEMENTIA
Dan Frenkel	Israel	THE LINK BETWEEN TAU TO BETA-AMYLOID: THE ASTROCYTES PERSPECTIVE
Giovanni Frisoni	SWITZERLAND	THE MEMORY CLINIC OF THE FUTURE: BRAIN HEALTH SERVICES FOR SECONDARY PREVENTION OF DEMENTIA AND COGNITIVE IMPAIRMENT
James Galvin	USA	BUILDING A BETTER BRAIN – USING PRECISION MEDICINE APPROACHES FOR DEMENTIA PREVENTION RESEARCH
Angela Genge	Canada	THE EVOLUTION OF BIOMARKERS AND OUTCOME MEASURES IN ALS DRUG DEVELOPMENT
Klaus Gerwert	Germany	PROTEIN MISFOLDING AS BIOMARKER FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS
Alison Goate	USA	ALZHEIMER'S DISEASE GENETICS IMPLICATES EFFEROCYTOSIS AND A DISEASE RISK HUB
Gabriel Gold	Switzerland	MICROVASCULAR LESIONS: THE CONCEALED THREAT TO OLD AGE COGNITION.
Todd Golde	USA	THE AMYLOID SCAFFOLD HYPOTHESIS
Maria Grazia Spillantini	UK	ASSOCIATION OF TMEM106B WITH HUMAN AGING
John Growdon	USA	TREATING DLB: CURRENT PRACTICE AND FUTURE DIRECTIONS
Christian Haass	Germany	MICROGLIAL FUNCTION AND DYSFUNCTION IN AD
Harald Hampel	USA	DESIGNING THE NEXT GENERATION CLINICAL CARE AND DIAGNOSTIC PATHWAY FOR ALZHEIMER'S DISEASE

Oskar Hansson	Sweden	FLUID AND IMAGING BIOMARKERS FOR ALZHEIMER'S AND PARKINSON'S DISEASES
Susanne Hendrix	USA	BUYING BACK TIME: THE UNIQUE TREATMENT IMPLICATIONS OF DISEASE MODIFYING THERAPIES
Michael Heneka	Germany	INNATE IMMUNE METABOLISM DETERMINES MICROGLIAL A β CLEARANCE CAPACITY
Joachim Herz	USA	THE EARLY ENDOSOME: A THERAPEUTIC HUB FOR THE PREVENTION OF ALZHEIMER'S DISEASE
Makato Higuchi	Japan	IN-VIVO IMAGING OF PROTEIN AGGREGATES IN DIVERSE NEURODEGENERATIVE DISORDERS: RELATION TO STRUCTURES OF PATHOLOGICAL FILAMENTS
Henne Holstege	The Netherlands	ESCAPING COGNITIVE DECLINE UNTIL EXTREME AGES: AN OMICS-STUDY OF COGNITIVELY HEALTHY CENTENARIANS
David Holtzman	USA	MICROGLIA-MEDIATED T CELL INFILTRATION DRIVES NEURODEGENERATION IN TAUOPATHY
Bradley Hyman	USA	UNDERSTANDING HETEROGENEITY IN ALZHEIMER DISEASE
Costantino Iadecola	USA	BORDER ASSOCIATED MACROPHAGES TAKE CENTER STAGE IN THE NEUROVASCULAR DYSFUNCTION OF APOE4
Ole Isaacson	USA	LIPID LOAD, EXCHANGE AND STORAGE INVOLVED IN THE DISEASE PROCESSES OF LEWY BODY DEMENTIA
Takeshi Iwatsubo	Japan	PET AND BIOMARKER CHARACTERIZATION OF PRECLINICAL AD IN THE JAPANESE TRIAL READY COHORT
Clifford Jack	USA	IN DEFENSE OF A BIOLOGICAL DEFINITION OF ALZHEIMER'S DISEASE
William Jagust	USA	ASSOCIATIONS WITH TAU AND COGNITION IN PRECLINICAL ALZHEIMER'S DISEASE
Beomseok Jeon	Korea	A MULTICENTER, CASE-CONTROL STUDY OF A-SYNUCLEIN ACCUMULATION IN THE GASTROINTESTINAL TRACT OF PARKINSON'S DISEASE
Jonathan Kipnis	USA	THE ROLE OF BRAIN BORDERS IN AD
Frank Laferla	USA	MODELING LATE-ONSET ALZHEIMER'S DISEASE IN MICE
Susan Landau	USA	TAU HETEROGENEITY IN ALZHEIMER'S DISEASE
Virginia Lee	USA	IN VITRO AND IN VIVO AMPLIFICATION OF PATHOLOGICAL AD-TAU AND LBD-A-SYNUCLEIN
Seung-Jae Lee	Korea	NEUROINFLAMMATION DRIVES COMPOUND PROTEINOPATHIES
Cynthia Lemere	USA	C3 LOWERING IN ADULT MICE PROTECTS AGAINST AGE-RELATED NEURODEGENERATION
Gregg Lemke	USA	THE DENSE-CORE PLAQUES OF ALZHEIMER'S DISEASE ARE GRANULOMAS
Stuart Lipton	USA	INHIBITION OF AUTOPHAGIC FLUX BY ABERRANT PROTEIN S-NITROSYLATION PROMOTES NEURONAL SECRETION AND CELL-TO-CELL TRANSMISSION OF AGGREGATED PROTEINS IN PARKINSON'S DISEASE/LEWY BODY DEMENTIA AND ALZHEIMER'S DISEASE
Eva Mandelkow	Germany	TREATMENTS AND REVERSAL OF TAU PATHOLOGY IN TRANSGENIC MICE
Eckhard Mandelkow	Germany	TAU PROTEIN: POSTTRANSLATIONAL MODIFICATIONS, AGGREGATION, AND CONDENSATION
Ken Marek	USA	DEVELOPING PD PRODROMAL BIOMARKER SIGNATURE TO SUPPORT PRODROMAL THERAPEUTIC TRIALS
Eliezer Masliah	USA	THE INTERPLAY BETWEEN AGING, THE IMMUNE SYSTEM AND ALPHA-SYNUCLEIN IN THE PATHOGENESIS OF DLB/PD
Pamela McLean	USA	PD THERAPIES TARGETING ALPHA-SYNUCLEIN
Daniel Michaelson	Israel	COUNTERACTING THE PATHOLOGICAL EFFECTS OF APOE4 BY ACTIVATION OF THE LIPIDATING PROTEIN ABCA1
Mark Mintun	USA	POTENTIAL ROLE OF PRECISION MEDICINE APPROACHES IN USING AMYLOID TARGETING THERAPIES
Asuka Morizane	Japan	MONITORING GRAFT SURVIVAL AND IMMUNE RESPONSE IN CELL REPLACEMENT THERAPY FOR PARKINSON'S DISEASE
John Morris	USA	ALZHEIMER BIOMARKER CORRELATIONS WITH MEASURES OF SOCIAL DETERMINANTS OF HEALTH
Ulrike Müller	Germany	HARNESSING THE PHYSIOLOGICAL FUNCTIONS OF APP FOR AD TREATMENT
Manuela Neumann	Germany	DISSECTING THE ROLE OF OLIGODENDROCYTES IN TDP-43 PROTEINOPATHIES
Henrietta Nielsen	Sweden	PERIPHERAL APOE-RELATED SIGNATURES

Tania Nikolcheva	Switzerland	LESSONS LEARNED FROM CLINICAL TRIALS IN ALZHEIMER'S AND PARKINSON'S DISEASES
Agneta Nordberg	Sweden	THE CLINICAL VALUE OF PLASMA BIOMARKERS IN A TERTIARY MEMORY CLINIC – A COMPARISON WITH IMAGING AND CSF BIOMARKERS
Miranda Orr	USA	CELLULAR SENESENCE AS A PATHOGENIC CONTRIBUTOR AND THERAPEUTIC TARGET IN ALZHEIMER'S DISEASE
Tiago Outeiro	Germany	GLYCATION AS A TARGET FOR INTERVENTION IN SYNUCLEINOPATHIES
Ronald Petersen	USA	FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT
Werner Poewe	Austria	EVOLVING CONCEPTS IN THE DIAGNOSIS OF PD
Marco Prado	Canada	IMPROVING RESEARCH TRANSLATION IN DEMENTIA: HUMANIZED MOUSE MODELS, COGNITION AND IMAGING
Gill Rabinovici	USA	ALZ-NET: A U.S.-WIDE REGISTRY TO TRACK LONGITUDINAL OUTCOMES IN PATIENTS TREATED WITH NOVEL AD THERAPIES IN REAL WORLD CLINICAL PRACTICE
Laura Ranum	USA	INTRONIC GGGAGA EXPANDED REPEATS IN CASP8 PRODUCE POLYGLYCINEARGININE PROTEINS THAT ACCUMULATE IN ALZHEIMER'S BRAINS AND INCREASE RISK OF DISEASE
Stephen Salloway	USA	NEW AND EMERGING TREATMENTS FOR ALZHEIMER'S DISEASE
Philip Scheltens	The Netherlands	ALZHEIMER: THE SEARCH FOR BETTER TARGETS AND MEANINGFUL OUTCOMES
Sjors Scheres	UK	CRYO-EM STRUCTURES OF AMYLOIDS FROM HUMAN BRAIN
Michael Schlossmacher	Canada	EXAMINATION OF THE OLFACTORY EPITHELIUM AND CRANIAL NERVE-1 IN AUTOPSY CASES OF COVID19 AND NEURODEGENERATION
Taylor Schmitz	Canada	TRANSLATIONAL POTENTIAL FOR MULTIMODAL IMAGING OF CHOLINERGIC PHENOTYPES IN MICE
Julie Schneider	USA	NEUROPATHOLOGY OF COGNITIVE AGING. WHAT TIPS THE BALANCE?
Menachem Segal	Israel	PRESENILIN AFFECTS MITOCHONDRIAL FUNCTIONS IN CULTURED HIPPOCAMPAL NEURONS: IMPLICATIONS FOR ALZHEIMER'S DISEASE
Jie Shen	USA	NOVEL THERAPIES OF FAMILIAL ALZHEIMER'S DISEASE
Tamara Shiner	Israel	IMAGING MARKERS IN GBA RELATED DEMENTIA WITH LEWY BODIES
Sam Sisodia	USA	THE GUT MICROBIOME MODULATES AD-LIKE PHENOTYPES IN MOUSE MODELS
Beka Solomon	Israel	ALZHEIMER'S DISEASE AND IMMUNOTHERAPY
Mona Soreq	Israel	TRANSFER RNA FRAGMENTS CARRYING A COMMON SEQUENCE MOTIF CAUSE SUPPRESSIBLE PARKINSON'S DISEASE NEURONAL DEATH VIA TRANSLATIONAL ARREST
Reisa Sperling	USA	AMYLOID, TAU, AND COGNITIVE DECLINE DURING THE PRECLINICAL STAGES OF ALZHEIMER'S DISEASE
Peter St. George-Hyslop	Canada	ROLE OF MICROGLIAL RISK AND RESILIENCE GENES IN REGULATING MICROGLIAL SIGNALLING AND FUNCTION
Beth Stevens	USA	NEUROIMMUNE MECHANISMS OF ALZHEIMER'S DISEASE : MAPPING GENETIC VARIANT TO FUNCTION IN BRAIN ASSOCIATED MACROPHAGES
Fabrizio Stocchi	Italy	NEW INSIGHT IN THE TREATMENT OF PARKINSONS DISEASE
Thomas Sudhof 🏆 Nobel Prize Winner	USA	CONNECTING LIPID METABOLISM TO SYNAPTIC DYSFUNCTION IN ALZHEIMER'S DISEASE
Malu Tansey	USA	TARGETING INNATE IMMUNE DYSFUNCTION AND CHRONIC INFLAMMATION IN THE GUT-BRAIN AXIS TO LOWER RISK AND PROGRESSION OF NEURODEGENERATION
Rudy Tanzi	USA	ALZHEIMER'S DISEASE IS A GENETICALLY COMPLEX AND HETEROGENEOUS INNATE IMMUNE DISORDER
Maria Teresa Ferretti	Switzerland	LEVERAGING SEX DIFFERENCES FOR IMPROVED PREVENTION, DIAGNOSTICS AND TREATMENT – THE WORK OF THE WOMEN'S BRAIN PROJECT
Li-Huei Tsai	USA	LIPID DYSREGULATION IS A COMMON PATHOGENIC MECHANISM OF MAJOR ALZHEIMER'S DISEASE RISK GENES
Christine Van Broeckhoven	Belgium	CONTRIBUTION OF RARE GENETIC VARIANTS TO NEURODEGENERATIVE BRAIN DISEASES
Robert Vassar	USA	ANNEXIN A6 OVEREXPRESSION REDUCES DYSTROPHIC NEURITE FORMATION AND PATHOLOGIC TAU PHOSPHORYLATION IN 5XFAD MICE
Yanning Wang	USA	FACTS AND MISCONCEPTIONS ABOUT ADUCANUMAB APPROVAL
Carina Wattmo	SWEDEN	SEX DIFFERENCES IN DISEASE PROGRESSION IN ALZHEIMER PATIENTS WITH DIFFERENT CONCOMITANT MEDICATIONS

Howard L. Weiner	USA	IMMUNOTHERAPY OF ALZHEIMER'S DISEASE BY MODULATION OF INNATE IMMUNITY
Michael Weiner	USA	USING DIGITAL AND FLUID BIOMARKERS FOR SCREENING AND SELECTION INTO THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE
Cheryl Wellington	Canada	LIPOPROTEINS IN ALZHEIMER'S DISEASE
Donna Wilcock	USA	DISEASE INSIGHTS FROM NOVEL PLASMA BIOMARKERS OF MULTI-ETIOLOGY DEMENTIA
Bengt Winblad	SWEDEN	DEVELOPMENT OF TREATMENT WITH SMALL MOLECULES FOR ALZHEIMER DISEASE
Henrik Zetterberg	Sweden	THE USE OF BLOOD BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIAL OUTCOMES
Jiawei Zhou	China	NON-CANONICAL ROLE OF INTESTINAL DOPAMINE RECEPTOR SIGNALLING IN NEURODEGENERATION
Berislav Zlokovic	USA	BLOOD-BRAIN BARRIER ROLE IN NEURODEGENERATION, COGNITIVE DECLINE AND ALZHEIMER'S DISEASE